prostatic hyperplasia

Summary

Summary: Enlargement or overgrowth of the PROSTATE gland as a result of an increase in the number of its constituent cells.

Top Publications

  1. doi Etiology, epidemiology, and natural history of benign prostatic hyperplasia
    Wade Bushman
    Department of Urology, University of Wisconsin Medical School, K6 562 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792, USA
    Urol Clin North Am 36:403-15, v. 2009
  2. doi The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study
    Claus G Roehrborn
    Department of Urology, UT Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Eur Urol 57:123-31. 2010
  3. doi Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients
    Oliver Reich
    Department of Urology, University Hospital Grosshadern, Ludwig Maximilians University Munich, Germany
    J Urol 180:246-9. 2008
  4. doi Update on AUA guideline on the management of benign prostatic hyperplasia
    Kevin T McVary
    American Urological Association Education and Research, Inc, Linthicum Maryland, USA
    J Urol 185:1793-803. 2011
  5. doi Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review
    Antonio Alcaraz
    Department of Urology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Eur Urol 55:864-73. 2009
  6. pmc Metabolic factors associated with benign prostatic hyperplasia
    J Kellogg Parsons
    Division of Urology, University of California San Diego, 200 West Arbor Drive, San Diego, California 21287, USA
    J Clin Endocrinol Metab 91:2562-8. 2006
  7. ncbi Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia
    Sara E Dahle
    Department of Epidemiology and Biostatistics, School of Public Health and Health Sciences, George Washington University, Washington, DC, USA
    J Urol 168:599-604. 2002
  8. ncbi The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia
    John D McConnell
    University of Texas Southwestern Medical Center, Dallas, TX 75390 9110, USA
    N Engl J Med 349:2387-98. 2003
  9. ncbi Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?
    Gero Kramer
    Department of Urology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Eur Urol 51:1202-16. 2007
  10. ncbi Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling
    J Luo
    Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287-2101, USA
    Cancer Res 61:4683-8. 2001

Detail Information

Publications414 found, 100 shown here

  1. doi Etiology, epidemiology, and natural history of benign prostatic hyperplasia
    Wade Bushman
    Department of Urology, University of Wisconsin Medical School, K6 562 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792, USA
    Urol Clin North Am 36:403-15, v. 2009
    Historically, benign prostatic hyperplasia (BPH) has been a major focus of urologic practice and surgery...
  2. doi The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study
    Claus G Roehrborn
    Department of Urology, UT Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Eur Urol 57:123-31. 2010
    ..provides significantly greater benefit than either monotherapy for various patient-reported outcomes in men with moderate-to-severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and prostatic enlargement.
  3. doi Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients
    Oliver Reich
    Department of Urology, University Hospital Grosshadern, Ludwig Maximilians University Munich, Germany
    J Urol 180:246-9. 2008
    ..has for decades been the standard surgical therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia, the most common benign neoplasm in men...
  4. doi Update on AUA guideline on the management of benign prostatic hyperplasia
    Kevin T McVary
    American Urological Association Education and Research, Inc, Linthicum Maryland, USA
    J Urol 185:1793-803. 2011
    To revise the 2003 version of the American Urological Association's (AUA) Guideline on the management of benign prostatic hyperplasia (BPH).
  5. doi Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review
    Antonio Alcaraz
    Department of Urology, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
    Eur Urol 55:864-73. 2009
    More than half the male population aged >50 yr have histologic evidence of benign prostatic hyperplasia (BPH), while prostate cancer (PCa) is among the most common male cancers according to recent registry data...
  6. pmc Metabolic factors associated with benign prostatic hyperplasia
    J Kellogg Parsons
    Division of Urology, University of California San Diego, 200 West Arbor Drive, San Diego, California 21287, USA
    J Clin Endocrinol Metab 91:2562-8. 2006
    Benign prostatic hyperplasia poses a significant public health problem, but its etiology remains unclear...
  7. ncbi Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia
    Sara E Dahle
    Department of Epidemiology and Biostatistics, School of Public Health and Health Sciences, George Washington University, Washington, DC, USA
    J Urol 168:599-604. 2002
    ..obesity is an important determinant of serum levels of insulin and leptin (the product of the obesity gene Ob), we investigated the role of obesity and serum levels of insulin and leptin in benign prostatic hyperplasia (BPH) etiology.
  8. ncbi The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia
    John D McConnell
    University of Texas Southwestern Medical Center, Dallas, TX 75390 9110, USA
    N Engl J Med 349:2387-98. 2003
    Benign prostatic hyperplasia is commonly treated with alpha-adrenergic-receptor antagonists (alpha-blockers) or 5alpha-reductase inhibitors...
  9. ncbi Is benign prostatic hyperplasia (BPH) an immune inflammatory disease?
    Gero Kramer
    Department of Urology, Medical University of Vienna, Wahringer Gurtel 18 20, A 1090 Vienna, Austria
    Eur Urol 51:1202-16. 2007
    Chronic inflammation has been documented for years in benign prostatic hyperplasia (BPH), but only now has it become evident as a major factor in disease progression...
  10. ncbi Human prostate cancer and benign prostatic hyperplasia: molecular dissection by gene expression profiling
    J Luo
    Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, Maryland 21287-2101, USA
    Cancer Res 61:4683-8. 2001
    ..of prostate cells, we performed gene expression profiling of primary human prostate cancer and benign prostatic hyperplasia (BPH) using cDNA microarrays consisting of 6500 human genes...
  11. doi The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH)
    Giorgio Gandaglia
    Department of Urology, Urological Research Institute, University Vita Salute San Raffaele, San Raffaele Scientific Institute, Milan, Italy
    BJU Int 112:432-41. 2013
    ..Patients with chronic inflammation and benign prostatic hyperplasia (BPH) have been shown to have larger prostate volumes, more severe lower urinary tract symptoms (LUTS) and ..
  12. ncbi Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7)
    Raymond Rosen
    Department of Psychiatry, Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, NJ 08854, USA
    Eur Urol 44:637-49. 2003
    ..This study was conducted to investigate the relationship between LUTS and sexual problems in aging men...
  13. ncbi Atherosclerosis as a risk factor for benign prostatic hyperplasia
    Andreas P Berger
    Department of Urology, Medical University of Innsbruck, Austria
    BJU Int 98:1038-42. 2006
    To evaluate the relationship between clinical benign prostatic hyperplasia (BPH) and atherosclerosis, using colour Doppler ultrasonography (CDUS) and symptom scores.
  14. doi Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial
    Claus G Roehrborn
    Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9110, USA
    Urology 78:641-6. 2011
    ..placebo on the symptoms and associated complications of male lower urinary tract symptoms and benign prostatic hyperplasia (BPH) across a range of prostate volumes and BPH symptoms in men evaluated for prostate cancer risk ..
  15. ncbi Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue
    Georg E Steiner
    Department of Urology, University of Vienna Medical School, Vienna, Austria
    Lab Invest 83:1131-46. 2003
    The aim of the study is to characterize the type of immune response in benign prostatic hyperplasia (BPH) tissue...
  16. doi Lifestyle factors, benign prostatic hyperplasia, and lower urinary tract symptoms
    J K Parsons
    UCSD Division of Urology, San Diego, CA 92103 8897, USA
    Curr Opin Urol 21:1-4. 2011
    Although age, genetics, and sex steroid hormones play prominent roles in the cause of benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), recent epidemiological studies suggest that modifiable lifestyle factors ..
  17. doi Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia
    Zhigang Zhao
    Department of Urology, The Second Affiliated Hospital, Shantou University Medical College, Guangdong Province, China
    Prostate 69:1292-302. 2009
    ..of the prostate (TURP)-resected tissues predicted the subsequent prostate cancer after TURP in benign prostatic hyperplasia (BPH) patients with both PSA < 4.0 ng/ml and normal DRE findings...
  18. ncbi Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development
    Hitoshi Ishiguro
    Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
    Prostate 64:92-100. 2005
    ..Advanced glycation end products (AGE) are produced with normal aging. Recently, some reports indicated that the interaction between AGE and the cognate receptor (RAGE) has a role in cancer dependent...
  19. ncbi Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer
    M J Linja
    Laboratory of Cancer Genetics, Institute of Medical Technology, University of Tampere and Tampere University Hospital, FIN-33014 Tampere, Finland
    Cancer Res 61:3550-5. 2001
    ..The two xenografts with the AR gene amplification will enable studies evaluating the functional significance of the amplification and development of new treatment strategies based on high-level expression of AR...
  20. doi The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation
    Cosimo De Nunzio
    Department of Urology, Sant Andrea Hospital, University La Sapienza, Rome, Italy
    Eur Urol 60:106-17. 2011
    Prostate cancer (PCa) is the most common cancer in the adult male, and benign prostatic hyperplasia (BPH) represents the most frequent urologic diagnosis in elderly males...
  21. doi Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions
    J Kellogg Parsons
    Division of Urologic Oncology, Moores Cancer Center, University of California San Diego and San Diego Veterans Affairs Medical Center, La Jolla, CA 92103, USA
    J Urol 189:S102-6. 2013
    Benign prostatic hyperplasia is a highly prevalent disease in older men with substantial adverse effects on public health. Classic etiological paradigms for benign prostatic hyperplasia focus on nonmodifiable risk factors...
  22. doi Relationship between prostatic urethral angle and urinary flow rate: its implication in benign prostatic hyperplasia pathogenesis
    Kang Su Cho
    Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea
    Urology 71:858-62. 2008
    ..The prostatic urethra is a bent tube, and the clinical significance of the prostatic urethral angle (PUA) is poorly understood. We investigated the effect of the PUA on the urinary flow rate in men without benign prostatic obstruction...
  23. ncbi Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia
    Claus G Roehrborn
    Department of Urology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390 9110, USA
    Urology 60:434-41. 2002
    ..To study the efficacy and safety of dutasteride, a dual inhibitor of the 5-alpha-reductase isoenzymes types I and II...
  24. ncbi Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia
    Jørgen Nordling
    Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
    BJU Int 95:1006-12. 2005
    To evaluate the efficacy and safety of two doses (10 and 15 mg) of alfuzosin once daily and tamsulosin (0.4 mg) once daily, compared with placebo, in men with benign prostatic hyperplasia (BPH).
  25. ncbi Vascular resistance in the prostate evaluated by colour Doppler ultrasonography: is benign prostatic hyperplasia a vascular disease?
    Andreas P Berger
    Department of Urology and Radiology, Medical University of Innsbruck, Austria
    BJU Int 98:587-90. 2006
    ..flow velocity using colour Doppler ultrasonography (CDUS), in normal prostates and in patients with benign prostatic hyperplasia (BPH) or prostate cancer, as BPH is considered to be a result of urogenital ageing and studies suggest ..
  26. ncbi Economic costs of benign prostatic hyperplasia in the private sector
    Christopher S Saigal
    Department of Urology, University of California Los Angeles, 90095 1738, USA
    J Urol 173:1309-13. 2005
    Several studies document the impact of benign prostatic hyperplasia (BPH) in working, aged men. Direct medical costs related to BPH treatment are largely borne by employees through higher premiums...
  27. ncbi The overlooked cause of benign prostatic hyperplasia: prostatic urethral angulation
    Kang Su Cho
    Department of Urology, Urological Science Institute, Yonsei University College of Medicine, 134 Shinchon dong, Seodaemun gu, Seoul, Republic of Korea
    Med Hypotheses 70:532-5. 2008
    Benign prostatic hyperplasia (BPH) is one of the most common problems faced by aging men and can be associated with bothersome lower urinary tract symptoms that affect quality of life by interfering with normal daily activities and sleep ..
  28. pmc Evaluation of prostatitis in autopsied prostates--is chronic inflammation more associated with benign prostatic hyperplasia or cancer?
    Nicolas B Delongchamps
    Department of Urology, State University of New York Upstate Medical University, New York 13210, USA
    J Urol 179:1736-40. 2008
    Chronic inflammation is associated with prostate cancer and benign prostatic hyperplasia. However, the prevalence of chronic inflammation in malignant and benign glands has not been compared...
  29. pmc Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial
    Jeannette M Schenk
    Cancer Prevention Program, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Am J Epidemiol 173:1419-28. 2011
    This study examined the association between symptomatic benign prostatic hyperplasia (BPH) and prostate cancer risk in 5,068 placebo-arm participants enrolled in the Prostate Cancer Prevention Trial (1993-2003)...
  30. doi Serum C-reactive protein levels are associated with residual urgency symptoms in patients with benign prostatic hyperplasia after medical treatment
    Chun Hou Liao
    Department of Urology, Cardinal Tien Hospital and College of Medicine, Ph D Program in Nutrition and Food Sciences, and Graduate Institute of Basic Medicine, Fu Jen Catholic University, Taipei, Taiwan
    Urology 78:1373-8. 2011
    Urinary urgency is a common and bothersome symptom in patients with benign prostatic hyperplasia (BPH); this symptom may persist even after medical treatment...
  31. doi Hormonal manipulation of benign prostatic hyperplasia
    Ferenc G Rick
    Veterans Affairs Medical Center, South Florida Veterans Affairs Foundation for Research and Education, University of Miami, Miller School of Medicine, Miami, Florida, USA
    Curr Opin Urol 23:17-24. 2013
    We provide new viewpoints of hormonal control of benign prostatic hyperplasia (BPH)...
  32. ncbi Impact of medical treatments for benign prostatic hyperplasia on sexual function
    Francois Giuliano
    Academic Hospital of Bicêtre, University of Paris South, France
    BJU Int 97:34-8; discussion 44-5. 2006
    ..Various treatment strategies for benign prostatic hyperplasia (BPH)/LUTS may affect sexuality, with differences between drug classes and between drugs within a same ..
  33. doi Lycopene for the prevention and treatment of benign prostatic hyperplasia and prostate cancer: a systematic review
    Dragan Ilic
    Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Vic, Australia
    Maturitas 72:269-76. 2012
    Prostate cancer is a leading cancer affecting men worldwide. Benign prostatic hyperplasia (BPH) is a common disease of the prostate affecting men as they age, and a risk factor for developing prostate cancer...
  34. pmc Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review
    Roderick MacDonald
    Minneapolis VA Center for Chronic Disease Outcomes Research, 1 Veterans Drive 111 0, Minneapolis, MN 55417, USA
    BJU Int 109:1756-61. 2012
    ..During the last 4 years we have seen two very high quality trials comparing Serenoa repens to placebo and up to 72 weeks' duration. These trials found Serenoa repens no better than placebo, even (in one trial) at escalating doses...
  35. doi A randomized, placebo-controlled study to assess safety and efficacy of vardenafil 10 mg and tamsulosin 0.4 mg vs. tamsulosin 0.4 mg alone in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia
    Mauro Gacci
    Department of Urology, University of Florence, Florence, Italy
    J Sex Med 9:1624-33. 2012
    Safety and efficacy of tamsulosin and vardenafil are well established: however, there is no report regarding combined therapy with these drugs for lower urinary tract symptoms (LUTSs) secondary to benign prostatic hyperplasia (BPH).
  36. ncbi Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract
    F K Habib
    Prostate Research Group, University Department of Oncology, Western General Hospital, Edinburgh, UK
    Prostate Cancer Prostatic Dis 7:195-200. 2004
    ..plant-derived medications for the treatment of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) state that every brand should be fully evaluated and considered separately...
  37. pmc Diabetes treatment and progression of benign prostatic hyperplasia in community-dwelling black and white men
    Aruna V Sarma
    Department of Urology, University of Michigan Medical School, Ann Arbor, Michigan 48109 2800, USA
    Urology 79:102-8. 2012
    To conduct a study to determine whether diabetes treatment is associated with benign prostatic hyperplasia (BPH)/lower urinary tract symptoms (LUTS) and progression in black and white men...
  38. doi Effects of Serenoa repens, selenium and lycopene (Profluss®) on chronic inflammation associated with benign prostatic hyperplasia: results of "FLOG" (Flogosis and Profluss in Prostatic and Genital Disease), a multicentre Italian study
    Giuseppe Morgia
    Department of Urology and Department of Hygiene and Public Health, University of Catania, Catania, Italy
    Int Braz J Urol 39:214-21. 2013
    ..To evaluate the efficacy of Profluss® on prostatic chronic inflammation (PCI)...
  39. pmc A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases
    Chong Xie
    Department of Urology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095 1738, USA
    J Transl Med 9:43. 2011
    ..One major obstacle is the lack of a sensitive and multiplex approach for quantifying autoAb against a large panel of clinically relevant tumor-associated antigens (TAA)...
  40. doi Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia
    Teruhiko Yokoyama
    Department of Urology, Kawasaki Medical School, Kurashiki, Okayama, Japan
    Int J Urol 18:225-30. 2011
    ..the effects of three different types of alpha-1 adrenoceptor blockers (α1-blocker) on lower urinary tract symptoms (LUTS), erectile dysfunction (ED) and ejaculatory dysfunction (EjD) in patients with benign prostatic hyperplasia.
  41. doi Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions
    J Kellogg Parsons
    Division of Urologic Oncology, Moores Cancer Center, University of California, San Diego, California, USA
    J Urol 182:S27-31. 2009
    Benign prostatic hyperplasia is a highly prevalent disease in older men with substantial adverse effects on public health. Classic etiological paradigms for benign prostatic hyperplasia focus on nonmodifiable risk factors...
  42. ncbi Oxidative stress and antioxidant status in non-metastatic prostate cancer and benign prostatic hyperplasia
    Ahmet Aydin
    Gulhane Military Medical Academy, Department of Toxicology, 06018 Etlik, Ankara, Turkey
    Clin Biochem 39:176-9. 2006
    We undertook the present study to investigate the possible alteration of oxidant/antioxidant status in the circulation of patients with prostate cancer and benign prostatic hyperplasia.
  43. doi Urological aspects of the metabolic syndrome
    Jan Hammarsten
    Department of Surgery, Section of Urology, Central Hospital, Rosenborgsgatan 2, S 652 30 Karlstad, Sweden
    Nat Rev Urol 8:483-94. 2011
    ..Most established aspects of the metabolic syndrome are linked to benign prostatic hyperplasia (BPH) and prostate cancer...
  44. ncbi Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia
    J Hammarsten
    Urological Section, Department of Surgery, Varberg Hospital, Varberg, Sweden
    Eur Urol 39:151-8. 2001
    ..To test the hypothesis of hyperinsulinaemia as a causal factor for the development of benign prostatic hyperplasia (BPH).
  45. pmc The accumulation of versican in the nodules of benign prostatic hyperplasia
    Lawrence D True
    Department of Pathology, University of Washington, Seattle, Washington 98195 6100, USA
    Prostate 69:149-58. 2009
    Proteoglycans, a complex group of extracellular matrix (ECM) molecules, are elevated in benign prostatic hyperplasia (BPH). Versican is a stromal proteoglycan present in prostate tissue...
  46. ncbi Comparison of intravesical prostatic protrusion, prostate volume and serum prostatic-specific antigen in the evaluation of bladder outlet obstruction
    Kok Bin Lim
    Department of Urology, Singapore General Hospital, Singapore
    Int J Urol 13:1509-13. 2006
    ....
  47. doi Subtypes of alpha1-adrenoceptors in BPH: future prospects for personalized medicine
    Yoshiyuki Kojima
    Department of Nephro urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
    Nat Clin Pract Urol 6:44-53. 2009
    ..muscle tone, and are a critical mediator of lower urinary tract symptoms and pathophysiology in benign prostatic hyperplasia (BPH). As a result, alpha(1)-AR antagonists are now used as first-line medical treatment for BPH...
  48. doi Outline of JUA clinical guidelines for benign prostatic hyperplasia
    Yukio Homma
    Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
    Int J Urol 18:741-56. 2011
    The Japanese Urological Association has developed Clinical Guidelines for Benign Prostatic Hyperplasia (BPH) for men with suspected BPH, which have been abridged and translated into English...
  49. doi Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial
    Matthias Oelke
    Department of Urology, Hannover Medical School, Hannover, Germany
    Eur Urol 61:917-25. 2012
    Tadalafil improved lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH; LUTS/BPH) in clinical studies but has not been evaluated together with an active control in an international clinical study.
  50. ncbi Physical activity and benign prostatic hyperplasia
    E A Platz
    Department of Epidemiology, Harvard School of Public Health, Boston, Mass 02115, USA
    Arch Intern Med 158:2349-56. 1998
    Benign prostatic hyperplasia (BPH) leading to prostatic enlargement and lower urinary tract symptoms is highly prevalent among older men...
  51. ncbi Alpha-adrenergic receptor antagonists in older patients with benign prostatic hyperplasia: issues and potential complications
    Shari R Fine
    Christ Hospital, Jersey City, NJ, USA
    J Am Osteopath Assoc 108:333-7. 2008
    Benign prostatic hyperplasia (BPH) is highly prevalent in men older than 50 years and is associated with a range of lower urinary tract symptoms that may have a negative impact on patient quality of life...
  52. doi Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia
    J Hammarsten
    Department of Urology, Skaraborg Hospital, Skovde, Sweden
    Prostate Cancer Prostatic Dis 12:160-5. 2009
    The aetiology of benign prostatic hyperplasia (BPH) remains unclear. The objective of the present study was to test the insulin, oestradiol and metabolic syndrome hypotheses as promoters of BPH...
  53. ncbi Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter st
    Kyu Sung Lee
    Department of Urology, Sungkyunkwan University School of Medicine, Seoul, Korea
    J Urol 174:1334-8. 2005
    ..We evaluated the efficacy and safety of a therapeutic modality involving propiverine combined with doxazosin in patients with overactive bladder (OAB) and benign prostatic obstruction...
  54. ncbi Seminal plasma cytokines and chemokines in prostate inflammation: interleukin 8 as a predictive biomarker in chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia
    Giuseppe Penna
    BioXell, Milan, Italy
    Eur Urol 51:524-33; discussion 533. 2007
    ..in seminal plasma of patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and benign prostatic hyperplasia (BPH), to evaluate inflammatory mediators as possible surrogate markers for diagnosis and treatment ..
  55. ncbi Evaluation of symptoms and quality of life in men with benign prostatic hyperplasia
    M J Barry
    Medical Practices Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA
    Urology 58:25-32; discussion 32. 2001
    Benign prostatic hyperplasia (BPH) is a common histologic condition among older men, which conveys its morbidity through lower urinary tract symptoms and complications, such as acute urinary retention, obstructive uropathy, and urinary ..
  56. ncbi Prostate cancer epidemiology
    Ann W Hsing
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland 20852 7234, USA
    Front Biosci 11:1388-413. 2006
    ..Results of these studies may lead to better detection, treatment, and, ultimately, prevention of prostate cancer...
  57. ncbi Symptomatic benign prostate hyperplasia: impact on partners' quality of life
    Dionisios Mitropoulos
    Department of Urology, University of Athens Medical School, 75, Mikras Asias Street, 115 27 Athens, Greece
    Eur Urol 41:240-4; discussion 244-5. 2002
    ..The present study was focused on exploring partner morbidity in cases of symptomatic BPH patients being evaluated for surgical treatment...
  58. doi The role of oxidative stress in prostate cancer
    Gaytri Gupta-Elera
    Department of Microbiology and Molecular Biology, Brigham Young University, Provo, UT 84602, USA
    Eur J Cancer Prev 21:155-62. 2012
    ..This review summarizes the effects of oxidative stress on the development of prostate cancer and explores the potential of ROS regulators as preventatives for prostate cancer...
  59. ncbi Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor
    Richard V Clark
    Clinical Pharmacology, GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina 27709, USA
    J Clin Endocrinol Metab 89:2179-84. 2004
    ..DHT is associated with development of benign prostatic hyperplasia (BPH), and reduction in its level with 5alpha-reductase inhibitors improves the symptoms associated with ..
  60. ncbi Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance
    Natasha Kyprianou
    Division of Urology, Department of Surgery, University of Kentucky Medical Center, Lexington, USA
    J Urol 169:1520-5. 2003
    ..This action alone however does not fully account for the long-term clinical responses exerted by these drugs in the treatment of patients with benign prostatic hyperplasia (BPH).
  61. ncbi Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer
    Lynn N Thomas
    Department of Biochemistry and Molecular Biology, Dalhousie University, Halifax, Nova Scotia, Canada
    Prostate 63:231-9. 2005
    ..However, inhibition of both 5alphaR isoenzymes causes a greater decrease in serum DHT. The aim of this study was to assess differential expression of these enzymes at various stages of PCa development...
  62. pmc Androgens and estrogens in benign prostatic hyperplasia: past, present and future
    Tristan M Nicholson
    University of Rochester School of Medicine and Dentistry, Rochester, NY, United States
    Differentiation 82:184-99. 2011
    Benign prostatic hyperplasia (BPH) and associated lower urinary tract symptoms (LUTS) are common clinical problems in urology...
  63. doi Combining growth hormone-releasing hormone antagonist with luteinizing hormone-releasing hormone antagonist greatly augments benign prostatic hyperplasia shrinkage
    Ferenc G Rick
    Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education, Miami, Florida 33125, USA
    J Urol 187:1498-504. 2012
    Benign prostatic hyperplasia often affects aging men. Antagonists of the neuropeptide growth hormone-releasing hormone reduced prostate weight in an androgen induced benign prostatic hyperplasia model in rats...
  64. ncbi Holmium laser enucleation versus transurethral resection of the prostate: results from a 2-center, prospective, randomized trial in patients with obstructive benign prostatic hyperplasia
    Francesco Montorsi
    Department of Urology, University Vita Salute, Scientific Institute Hospital San Raffaele, Milan, Italy
    J Urol 172:1926-9. 2004
    To our knowledge we report the first multicenter, prospective, randomized study comparing holmium laser enucleation (HoLEP) and transurethral prostate resection (TURP) for obstructive benign prostatic hyperplasia.
  65. ncbi Urologic diseases in America project: benign prostatic hyperplasia
    John T Wei
    Department of Urology, University of Michigan, Ann Arbor, USA
    J Urol 173:1256-61. 2005
    Benign prostatic hyperplasia (BPH), the most common benign neoplasm in American men, is a chronic condition that is associated with progressive lower urinary tract symptoms and affects almost 3 of 4 men during the seventh decade of life...
  66. pmc Prostate stem cells and benign prostatic hyperplasia
    John T Isaacs
    Department of Oncology, The Chemical Therapeutics Program, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, USA
    Prostate 68:1025-34. 2008
    ....
  67. ncbi Use of multiple biomarkers for a molecular diagnosis of prostate cancer
    Kelly A Landers
    Department of Surgery, Central Clinical Division, School of Medicine, University of Queensland, Herston, Queensland 4072, Australia
    Int J Cancer 114:950-6. 2005
    ..Supplemental material for this article can be found on the International Journal of Cancer website at http://www.interscience.wiley.com/jpages/0020-7136/suppmat/index.html.)..
  68. ncbi Expression of heme oxygenase-1 (HSP32) in human prostate: normal, hyperplastic, and tumor tissue distribution
    M D Maines
    Department of Biophysics, University of Rochester School of Medicine, NY 14642, USA
    Urology 47:727-33. 1996
    ..The aim of this study was to examine the pattern of tissue expression of HO-1 in the human prostate under different states of proliferation and differentiation and to investigate whether the pattern differs between these states...
  69. ncbi Expression of cyclooxygenase-2 in prostate adenocarcinoma and benign prostatic hyperplasia
    L M Lee
    Department of Urology, Taipei Medical University-Affiliated Taipei Municipal Wan-Fang Hospital, Taiwan, Republic of China
    Anticancer Res 21:1291-4. 2001
    ..the potential prognostic role of COX-2 in prostate cancer, we assessed the expression of COX-2 in benign prostatic hyperplasia (BPH) and prostate cancer samples employing immunohistochemistry...
  70. doi Bipolar versus monopolar transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials
    Charalampos Mamoulakis
    Department of Urology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
    Eur Urol 56:798-809. 2009
    ..Incorporation of bipolar technology in transurethral resection (TUR) of the prostate (TURP) potentially offers advantages over monopolar TURP (M-TURP)...
  71. ncbi The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia
    Cuneyt Ozden
    Department of Urology, Numune Education and Research Hospital, Ankara, Turkey
    Eur Urol 51:199-203; discussion 204-6. 2007
    To evaluate the relationship between metabolic syndrome and annual prostatic growth rates in benign prostatic hyperplasia (BPH) patients.
  72. ncbi Diagnostic accuracy of noninvasive tests to evaluate bladder outlet obstruction in men: detrusor wall thickness, uroflowmetry, postvoid residual urine, and prostate volume
    Matthias Oelke
    Department of Urology, Academic Medical Center, University of Amsterdam, The Netherlands
    Eur Urol 52:827-34. 2007
    ....
  73. ncbi A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder
    Christopher R Chapple
    The Royal Hallamshire Hospital, Sheffield, UK
    Eur Urol 49:651-8. 2006
    ....
  74. pmc 5α-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression
    Alejandro Godoy
    Department of Urology, Roswell Park Cancer Institute, Buffalo, New York 14263, USA
    Prostate 71:1033-46. 2011
    ..A third isozyme of human 5α-steroid reductase, 5α-reductase-3, was identified in prostate tissue at the mRNA level. However, the levels of 5α-reductase-3 protein expression and its cellular localization in human tissues remain unknown...
  75. doi Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging
    Aytekin Oto
    Department of Radiology, University of Chicago, 5841 S Maryland Ave, MC 2026, Chicago, IL 60637, USA
    Radiology 257:715-23. 2010
    ....
  76. pmc Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis
    Gregoire Robert
    INSERM U955 Eq07, Creteil, France
    Prostate 69:1774-80. 2009
    Prostatic inflammation could be a key component in prostate enlargement and benign prostatic hyperplasia (BPH) progression...
  77. doi Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH Registry
    Raymond C Rosen
    New England Research Institutes, Watertown, Massachusetts 02472, USA
    Urology 73:562-6. 2009
    ..ED and EjD are also side effects of some medical therapies for LUTS suggestive of benign prostatic hyperplasia (LUTS/BPH)...
  78. ncbi CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer
    Hideki Enokida
    Department of Urology, University of California, San Francisco, California 94121, USA
    Cancer Res 64:5956-62. 2004
    ..These findings suggest that CpG hypermethylation of MDR1 promoter is a frequent event in prostate cancer and is related to disease progression via increased cell proliferation in prostate cancer cells...
  79. ncbi Molecular and cellular pathogenesis of benign prostatic hyperplasia
    Keith L Lee
    Department of Urology, Stanford University School of Medicine, Stanford, California 94305 5118, USA
    J Urol 172:1784-91. 2004
    Symptomatic benign prostatic hyperplasia (BPH) is one of the most common ailments seen by the urologist. Significant advances have occurred in medical and surgical therapy, and in the understanding of the biology of this disease...
  80. doi Expression of toll-like receptor-9 is increased in poorly differentiated prostate tumors
    Marja Riitta Väisänen
    Department of Pathology, Oulu University Hospital, Oulu, Finland
    Prostate 70:817-24. 2010
    ..Other studies have suggested possible sex steroid regulation of the function of the various TLRs. The role of TLR9 in the pathophysiology of prostate or any cancer is, however, unknown...
  81. ncbi Alterations in gap junction protein expression in human benign prostatic hyperplasia and prostate cancer
    Helga Habermann
    Department of Urology, University of Graz, Graz, Austria
    J Urol 167:655-60. 2002
    ..cancer is controversial, while to our knowledge connexin expression has not been reported in benign prostatic hyperplasia (BPH)...
  82. ncbi Asymptomatic inflammation and/or infection in benign prostatic hyperplasia
    J C Nickel
    Department of Urology, Queen s University, Kingston, Ontario, Canada
    BJU Int 84:976-81. 1999
    To determine the extent, pattern and clinical significance of asymptomatic histological inflammation and latent infection (National Institute of Health Category IV prostatitis) in benign prostatic hyperplasia (BPH).
  83. pmc A system for studying epithelial-stromal interactions reveals distinct inductive abilities of stromal cells from benign prostatic hyperplasia and prostate cancer
    Wendy W Barclay
    Department of Cancer Biology, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157, USA
    Endocrinology 146:13-8. 2005
    ..different pathologies, and we compared the abilities of stromal cells from normal peripheral zone, benign prostatic hyperplasia (BPH-S), and cancer to induce the growth of a human prostatic epithelial cell line (BPH-1) in vivo...
  84. ncbi Prostatic MR imaging. Accuracy in differentiating cancer from other prostatic disorders
    S Ikonen
    Department of Radiology, Helsinki University Central Hospital, and The Finnish Institute of Occupational Health, Helsinki, Finland
    Acta Radiol 42:348-54. 2001
    ..Twenty patients had prostatic cancer, 20 benign prostatic hyperplasia (BPH), 4 acute bacterial prostatitis, 5 chronic bacterial prostatitis (2 also belonging to the previous ..
  85. ncbi Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis
    Franco Di Silverio
    Department of Urology U Bracci, University La Sapienza, V Policlinico, 00161, Rome, Italy
    Eur Urol 43:164-75. 2003
    ..We analyze our experience on BPH through 20 years of histopathological examinations performed by the same pathologist...
  86. doi Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation
    Giuseppe Penna
    BioXell, Milan, Italy
    J Immunol 182:4056-64. 2009
    Benign prostatic hyperplasia (BPH), a highly prevalent prostatic condition, could involve an inflammatory component in disease pathogenesis...
  87. pmc A role for epithelial-mesenchymal transition in the etiology of benign prostatic hyperplasia
    Paloma Alonso-Magdalena
    Department of Biosciences and Nutrition, Karolinska Institute, Novum, SE 141 86 Huddinge, Sweden
    Proc Natl Acad Sci U S A 106:2859-63. 2009
    Benign prostatic hyperplasia (BPH) is usually described as a pathological proliferation of prostatic fibroblasts/myofibroblasts and epithelial cells...
  88. ncbi Could inflammation be a key component in the progression of benign prostatic hyperplasia?
    Gero Kramer
    Department of Urology, Medical University of Vienna, Austria
    Curr Opin Urol 16:25-9. 2006
    This review covers recent developments in the role of chronic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH).
  89. ncbi Association of hypertension with symptoms of benign prostatic hyperplasia
    Martin C Michel
    Department of Pharmacology and Pharmacotherapy, University of Amsterdam, Amsterdam, The Netherlands
    J Urol 172:1390-3. 2004
    We determined whether the intensity of benign prostatic hyperplasia (BPH) symptoms and arterial hypertension are associated.
  90. pmc Effects of flavocoxid, a dual inhibitor of COX and 5-lipoxygenase enzymes, on benign prostatic hyperplasia
    D Altavilla
    Department of Clinical and Experimental Medicine and Pharmacology, Section of Pharmacology, University of Messina, Messina, Italy
    Br J Pharmacol 167:95-108. 2012
    Inflammation plays a key role in the development of benign prostatic hyperplasia (BPH). Eicosanoids derived from the COX and 5-lipoxygenase (5-LOX) pathways are elevated in the enlarging prostate...
  91. pmc Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment
    Tristan M Nicholson
    Department of Urology, University of Wisconsin, Madison, WI, USA
    Differentiation 85:140-9. 2013
    Androgens and estrogens, acting via their respective receptors, are important in benign prostatic hyperplasia (BPH)...
  92. pmc An open, comparative, multicentre clinical study of combined oral therapy with sildenafil and doxazosin GITS for treating Chinese patients with erectile dysfunction and lower urinary tract symptoms secondary to benign prostatic hyperplasia
    Zhe Jin
    Andrology Center, Peking University First Hospital, Peking University, Beijing 100034, China
    Asian J Androl 13:630-5. 2011
    ..Chinese patients with erectile dysfunction (ED) and lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH/LUTS)...
  93. doi Estrogen and androgen signaling in the pathogenesis of BPH
    Clement K M Ho
    Department of Biochemistry, Raigmore Hospital, Old Perth Road, Inverness IV2 3UJ, UK
    Nat Rev Urol 8:29-41. 2011
    Estrogens and androgens have both been implicated as causes of benign prostatic hyperplasia (BPH)...
  94. doi Evaluating use patterns of and adherence to medications for benign prostatic hyperplasia
    Michael B Nichol
    Department of Clinical Pharmacy and Pharmaceutical Economics and Policy, University of Southern California, Los Angeles, California 90089, USA
    J Urol 181:2214-21; discussion 2221-2. 2009
    We investigated adherence to benign prostatic hyperplasia medications in a California Medicaid population.
  95. doi A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia
    Mauro Gacci
    Department of Urology, University of Florence, Florence, Italy
    Eur Urol 61:994-1003. 2012
    ..However, the results are inconsistent...
  96. pmc Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia
    Richard Olivier Fourcade
    Department of Urology, Centre Hospitalier Auxerre, Auxerre, France
    World J Urol 30:419-26. 2012
    ....
  97. doi Occupational physical activity in relation with prostate cancer and benign prostatic hyperplasia
    Areti Lagiou
    Faculty of Health Professions, Athens Technological Institute, University of Athens, Athens, Greece
    Eur J Cancer Prev 17:336-9. 2008
    ..examined the association of occupational physical activity with the risk of prostate cancer and benign prostatic hyperplasia (BPH)...
  98. doi LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia
    Ferenc G Rick
    Veterans Affairs Medical Center and South Florida Veterans Affairs Foundation for Research and Education, Miami, Florida 33125, USA
    Prostate 71:736-47. 2011
    ..We investigated the mechanism of action and effect of Cetrorelix in a rat model of BPH...
  99. ncbi Risk behaviours and benign prostatic hyperplasia
    D Kang
    Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, South Korea
    BJU Int 93:1241-5. 2004
    To identify risk factors for benign prostatic hyperplasia (BPH).
  100. doi Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells
    Linda Vignozzi
    Sexual Medicine and Andrology Unit, Department of Clinical Physiopathology, University of Florence, Viale Pieraccini 6, Florence 50139, Italy
    J Endocrinol 214:31-43. 2012
    Progression of benign prostatic hyperplasia (BPH) involves chronic inflammation and immune dysregulation...
  101. doi Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH)
    Claus G Roehrborn
    Department of Urology, UT Southwestern Medical Center, 5323 Harry Hines Boulevard, J8 142, Dallas, TX 75390 9110, USA
    Med Clin North Am 95:87-100. 2011
    Male lower urinary tract symptoms, benign prostatic hyperplasia, enlargement of the prostate, and bladder outlet obstruction are common among aging men and will increase in socioeconomic and medical importance at a time of increased life ..

Research Grants76

  1. Mechanism of Bladder Overactivity in Pelvic Ischemia
    Kazem M Azadzoi; Fiscal Year: 2013
    ..In the elderly male, bladder outlet obstruction due to benign prostatic hyperplasia (BPH) has long been blamed...
  2. PKC/PKA Regulation in Prostate Cancer by SSeCKS/Gravin/AKAP12
    Irwin H Gelman; Fiscal Year: 2013
    ..CaP metastasis growth by inhibiting VEGF-induced neovascularization, genetic knockout (KO) in mice induces prostatic hyperplasia and focal dysplasia with evidence of epithelial cell senescence, and KO mouse fibroblasts (MEF) display ..
  3. Chemoprevention of Prostate Cancer
    SUSAN AUDREY HALL; Fiscal Year: 2012
    ..unanswered questions remain regarding finasteride, a 5-alpha reductase inhibitor currently used for benign prostatic hyperplasia that may also protect against prCA...
  4. TR4 orphan receptor, a longevity assurance gene, in prostate carcinogenesis
    Yi Fen Lee; Fiscal Year: 2012
    ..A few surviving "aged" TR4-/- mice developed abnormal proliferative lesions of prostatic hyperplasia and/or dysplasia at the age of 17 months while wild type littermates retained an intact prostatic ..
  5. Validation of Biomarkers to Distinguish Aggressive from Indolent Prostate Cancer
    George Wilding; Fiscal Year: 2013
    ..expression in several resected prostate tissue microarrays (TMA) consisting of normal prostate, benign prostatic hyperplasia (BPH), prostatic intraepithelial neoplasia (PIN), localized low grade PCa, high grade PCa and metastatic ..
  6. Development of Nonhuman Primate Models for PSA Biology Studies
    JAMES NKAMBWE MUBIRU; Fiscal Year: 2013
    Common prostatic diseases include prostate cancer, benign prostatic hyperplasia (BPH) and prostatitis. These diseases are a cause of significant mortality and morbidity...
  7. Mechanisms of Fatty Acid Metabolism in Prostate Differentiation and Disease
    DOUGLAS WILLIAM STRAND; Fiscal Year: 2013
    ..Benign prostatic hyperplasia and associated lower urinary tract symptoms (BPH/LUTS) are a severe physical and financial burden, which, ..
  8. Radiation Force Imaging of Prostate Cancer and Guidance of Biopsy Procedures
    Kathryn Radabaugh Nightingale; Fiscal Year: 2013
    ..g., benign prostatic hyperplasia (BPH) and inflammation)...
  9. Prostate Cancer Detection by Molecular Urinalysis
    Christian P Pavlovich; Fiscal Year: 2010
    ..One out of six American men is diagnosed with prostate cancer in his lifetime, and 1/2 develops benign prostatic hyperplasia (BPH). The Prostate Cancer Prevention Trial recently demonstrated a 25% incidence of prostate cancer in U...
  10. Estrogen Regulation in BPH and the Lower Urinary Tract
    WILLIAM ALLEN RICKE; Fiscal Year: 2013
    ..Benign prostatic hyperplasia (BPH) occurs in a vast majority of men and contributes to the morbidity known as LUTS...
  11. Obesity, Inflammation and BPH
    Simon W Hayward; Fiscal Year: 2013
    ..is brings together a multidisciplinary team to determine the role of obesity in the development of benign prostatic hyperplasia (BPH)...
  12. Role of U19/Eaf2 in androgen-dependent prostate homeostasis
    Zhou Wang; Fiscal Year: 2013
    ..Androgens play important roles in the pathogenesis of prostate cancer and benign prostatic hyperplasia (BPH), two major diseases in American men at old age...
  13. Initiation and Regulation of Chronic Autoimmune Prostate Inflammation
    Timothy L Ratliff; Fiscal Year: 2013
    ..multiple prostate diseases including chronic prostatitis-chronic pelvic pain syndrome (CP-CPPS), benign prostatic hyperplasia (BPH), and prostate cancer...
  14. Excitation contraction coupling in bladder smooth muscle
    Robert S Moreland; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): The prevalence of benign prostatic hyperplasia (BPH) increases as men age...
  15. Multi-disciplinary Training in Benign Urology
    Hunter Wessells; Fiscal Year: 2013
    ..anomalies, kidney stones, urinary incontinence, erectile dysfunction, lower urinary tract symptoms, benign prostatic hyperplasia, pelvic pain and urethral strictures affect millions of persons and account for over 3...
  16. Paracrine Regulation of BPH Pathogeneis
    SIMON HAYWARD; Fiscal Year: 2009
    PROJECT SUMMARY: Benign prostatic hyperplasia (BPH) is an important cause of morbidity in the adult male population and is the most common symptomatic tumor-like condition in humans...
  17. Paracrine Regulation of BPH Pathogenesis
    Simon W Hayward; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Benign prostatic hyperplasia (BPH) is an important cause of orbidity in the adult male population and is the most common symptomatic tumor-like condition in humans...
  18. Estrogen receptors in benign prostatic hyperplasia
    TRISTAN MARRINER NICHOLSON; Fiscal Year: 2013
    ..The goal of this fellowship research will be to elucidate the ER underlying induction of these effects in this mouse model and evaluate SERMs as potential therapies for BPH. ..
  19. A bioelectronic assay for PSA activity
    Dimitra Georganopoulou; Fiscal Year: 2010
    ..However, an enlarged prostate due to benign prostatic hyperplasia (BPH) also leads to increased concentrations of PSA in serum...
  20. Does doxazosin attenuate stress-induced smoking and improve clinical outcomes?
    SHERRY ANN MCKEE; Fiscal Year: 2012
    ..Doxazosin (Cardura(R), Pfizer, marketed for hypertension and benign prostatic hyperplasia) is an alpha-1 agent similar to prazosin, but has a longer half-life (22hrs) improving the likely ..
  21. Murine slow onset outlet obstruction as a model of human voiding dysfunction
    Ronald W Wood; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Aging men manifest Benign Prostatic Hyperplasia (BPH) that can result in lower urinary tract symptoms (LUTS), decreased flow, prolonged voiding, detrusor instability (Dl), nocturia, retention, and ..
  22. Steroid hormones and SFRP1 in the age-related incidence of BPH and BOO
    Paul C Marker; Fiscal Year: 2013
    ..causes of BOO are unclear and may be multi-factorial, BOO is often found in association with benign prostatic hyperplasia (BPH), another highly prevalent condition in aging men...
  23. Biomarkers of Obesity, Prostate Tissue Inflammation, and BPH Progression
    Jay H Fowke; Fiscal Year: 2013
    ..Several prior prospective studies report obesity is associated with clinical symptoms of benign prostatic hyperplasia (BPH)...
  24. Role of Inflammation and Epigenetics in Benign Prostate Pathology
    Charles J Bieberich; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Lower urinary tract symptoms associated with benign prostatic hyperplasia and prostatitis have a profound impact on quality of life...
  25. ENERGY BALANCE AND RISK OF BPH-RELATED OUTCOMES AND LUTS: A PROSPECTIVE STUDY
    Siobhan Sutcliffe; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Benign prostatic hyperplasia (BPH) is a benign prostate condition characterized histologically by hyperplastic nodules in the periurethral region and transition zone of the prostate, and clinically ..
  26. Androgen signaling in benign prostatic hyperplasia (BPH)
    Zhou Wang; Fiscal Year: 2013
    ..about 30% of men aged 50 and over and is generally considered a sign of clinically significant benign prostatic hyperplasia (BPH). Androgens and aging are two known important factors in BPH pathogenesis...
  27. Prostatic Inflammation Induces Neurovascular Changes
    WADE A BUSHMAN; Fiscal Year: 2012
    DESCRIPTION (provided by applicant): Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) are generally thought to result from the combined effects of prostate enlargement and age-related changes in ..
  28. Biomarkers predicting the severity of obstruction-induced bladder dysfunction
    Robert M Levin; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Bladder dysfunction secondary to benign prostatic hyperplasia (BPH) is a major affliction of aging men. BPH can initiate changes associated with lower urinary tract symptoms (LUTS)...
  29. Reduced Levels of 5-alpha Reductase 2 in Adult Prostate Tissue and BPH Therapy
    Aria F Olumi; Fiscal Year: 2013
    ..are commonly used for medical management of patients with obstructive uropathy secondary to benign prostatic hyperplasia (BPH). Finasteride, the most commonly used 5-1 reductase inhibitor, is prescribed to 8...
  30. The Role of MicroRNAs in Prostate Cancer Progression
    AURORA ESQUELA KERSCHER; Fiscal Year: 2010
    ..including insignificant and micrometastatic disease compared to non-cancerous specimens from benign prostatic hyperplasia (BPH) patients and normal prostate tissues via miRNA microarray analysis and quantitative real-time PCR;2) ..
  31. OnabotulinumtoxinA (onaVoNT-A) vs Oral Tamsulosin for PBH &LUTS (#02-10-10-05)
    Christopher P Smith; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Benign prostatic hyperplasia (BPH) and its related symptoms are a common condition that affects nearly half of men over age 50 and 90% of men over 80...
  32. A Nanotechnology Enabled Diagnostic Platform for Early Stage Cancer Detection
    James C Nelson; Fiscal Year: 2012
    ..and validation of an accurate, low cost diagnostic test that can discriminate prostate cancer from benign prostatic hyperplasia to a Specificity of 85% at a Sensitivity of 85%...
  33. Interleukin-8 Induced Biology in Benign Prostatic Hyperplasia
    David Rowley; Fiscal Year: 2009
    Benign prostatic hyperplasia (BPH) is a common age-associated disorder typified by epithelial and stromal hyperplasia and progressive enlargement of the prostate gland...
  34. Doxazosin an a1 Antagonist for Alcohol Dependence
    GEORGE ANTHONY KENNA; Fiscal Year: 2012
    ..Prazosin is a short-acting a1-blocker approved to treat hypertension (HTN) and benign prostatic hyperplasia (BPH)...
  35. Interleukin-8 Induced Biology in Benign Prostatic Hyperplasia
    David R Rowley; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Benign prostatic hyperplasia (BPH) is typified by epithelial and stromal hyperplasia and progressive enlargement of the prostate gland...
  36. Spatiotemporal Modulation of PIP[3]Signaling in Prostatic Tubulogenesis
    Tamara L Lotan; Fiscal Year: 2013
    ..regulate prostatic growth during embryonic development are reactivated in adult diseases, such as benign prostatic hyperplasia and cancer...
  37. Development of Metabolomic and Molecular Probes for Prostate Cancer Assessment
    Leo L Cheng; Fiscal Year: 2012
    ..hZIP1, for different pathological components isolated with LCM from patients of clinically proven benign prostatic hyperplasia (BPH), prostatrophic hyperplasia (PAH), prostatic intraepithelial neoplasm (PIN), and different grades of ..
  38. Prostate carcinogenesis and PKC signaling
    MARCELO GABRIEL KAZANIETZ; Fiscal Year: 2013
    ..Interestingly, PB-PKCe transgenic mice developed prostatic hyperplasia and intraepithelial neoplastic (PIN) lesions, whereas no obvious phenotype was observed in similar models ..
  39. Hollow Fiber Catheter for Drug Delivery into the Prostate
    JIM STICE; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Significance: Benign Prostatic Hyperplasia (BPH) will become an increasing burden on economic resources with the aging population...
  40. Cellular Senescence in the Pathogenesis of Benign Prostatic Hyperplasia
    Michael M Ittmann; Fiscal Year: 2012
    ..Benign prostatic hyperplasia (BPH) is the single most common pathology of aging men...
  41. University of Pittsburgh Urologic Training Program for Scientists
    Zhou Wang; Fiscal Year: 2013
    ..on many of the key mechanisms underlying urologic diseases, including the molecular biology of benign prostatic hyperplasia, prostate growth regulation, androgen action, inflammation, and neuron-epithelial interactions...
  42. Complementary and Alternative Medicine for Urological Symptoms (CAMUS)
    Andrew L Avins; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Benign prostatic hyperplasia (BPH) is a common problem for older men. Several treatment options exist for BPH, including watchful waiting, prescription medications, and invasive procedures...
  43. Measuring the Impact of the Rapid Expansion of MIST Procedures for BPH
    ALEXANDER M MCBEAN; Fiscal Year: 2010
    DESCRIPTION (provided by applicant): Benign prostatic hyperplasia is one of the most common chronic conditions among America men. The traditional, `gold standard', surgical treatment is transuretheral prostatectomy (TURP)...
  44. Imaging Feedback to Guide Ultrasonic Tissue Fractionation for Cancer Therapy
    CHARLES ALAN CAIN; Fiscal Year: 2012
    ..g., prostate cancer, benign prostatic hyperplasia (BPH), breast cancer, fibroadenomas of the breast, liver cancer and metastases, kidney cancer, uterine ..
  45. Urinary Biomarkers of Lower Urinary Traxct Symptoms (LUTS) in Men
    WADE A BUSHMAN; Fiscal Year: 2013
    ..Plausible etiologies for LUTS include, but are not limited to, benign prostatic hyperplasia, inflammation in the prostate and bladder neck, changes in smooth muscle tone in the prostate and bladder ..
  46. Androgenic Regulation of Autophagy in the Prostate
    DANIEL EDWARD FRIGO; Fiscal Year: 2012
    ..is to develop new therapeutic approaches for the treatment of endocrine-regulated diseases such as benign prostatic hyperplasia (BPH)...
  47. Receptor tyrosine kinase signaling in the control of Prostate Development
    GAIL ROBERTA MARTIN; Fiscal Year: 2010
    ..In adulthood the prostate can undergo pathological changes, including benign prostatic hyperplasia and prostate adenocarcinoma...
  48. Mechanisms of Cytokine Induced Lower Urinary Track Pathology
    Michael M Ittmann; Fiscal Year: 2013
    ..provided by applicant): By the 8th decade of life approximately 80% of men have evidence of benign prostatic hyperplasia (BPH), which is characterized by markedly increased tissue mass in the transition zone (TZ) of the ..
  49. Role of Pim Kinases in Prostate Epithelium Growth
    Bo Cen; Fiscal Year: 2013
    ..HEALTH RELEVANCE: The proposed research will lead to a better understanding of the mechanisms of benign prostatic hyperplasia (BPH), effecting more than 50% of all men in their sixties and up to 90% of men in their seventies and ..
  50. Alternative Therapies for Benign Prostate Symptoms
    Karl J Kreder; Fiscal Year: 2011
    ..the effect of phytotherapy using Sernoa repens (saw palmetto) and Pygeum africanum in men with benign prostatic hyperplasia (BPH)...
  51. Histotripsy Tissue Interactions for BPH Therapy
    William W Roberts; Fiscal Year: 2013
    ..within the prostate, specifically assessing the suitability of histotripsy for treatment of benign prostatic hyperplasia (BPH)...
  52. Alternative Therapies for Benign Prostate Symptoms
    Andrew R McCullough; Fiscal Year: 2010
    ..Subjects in this trial suffer from benign prostatic hyperplasia and lower urinary tract symptoms, more commonly known as BPH/LUTS...
  53. Differentiation Signaling in Prostate Stem Cells
    WENDY JOY HUSS; Fiscal Year: 2013
    ..option for prostatic diseases that are caused by an unregulated stem cell niche including benign prostatic hyperplasia (BPH). The hypothesis is tested in three specific aims: 1...
  54. Role of Pattern Recognition Receptors in Prostate Epithelial Inflammation
    Praveen Thumbikat; Fiscal Year: 2013
    ..PUBLIC HEALTH RELEVANCE: The proposed research will lead to a better understanding of the mechanisms of a number of urologic diseases including prostatitis and benign prostatic hyperplasia (BPH), conditions affecting millions of men.
  55. PRIMARY-CARE VERSUS UROLOGIST MANAGEMENT OF BENIGN PROSTATIC HYPERPLASIA
    SETH ADAM STROPE; Fiscal Year: 2013
    ..As the most common benign neoplasm among American men, and a leading cause for urologic referral, benign prostatic hyperplasia (BPH) has a significant impact on health in the United States...
  56. Role of mTORC1 In The Regulation Of Prostatic Branching Morphogenesis
    Tamara L Lotan; Fiscal Year: 2013
    ..is of particular relevance because conditions of abnormal prostatic growth in the adult, such as benign prostatic hyperplasia, are undoubtedly regulated by many of the same signaling networks active during embryonic prostate ..
  57. Histotripsy for Benign Prostatic Hyperplasia
    William W Roberts; Fiscal Year: 2010
    ..ultrasound therapy that produces non-thermal mechanical tissue destruction) as a therapy for benign prostatic hyperplasia (BPH)...
  58. Novel Translational Approaches to BPH/LUTS
    Robert H Getzenberg; Fiscal Year: 2011
    Benign Prostatic Hyperplasia (BPH) or Lower Urinary Tract Symptoms (LUTS) represents one of the most common diseases occurring in aging men in the United States...
  59. Clinical Evaluation and Treatment Center for BPH
    GERALD LOUIS ANDRIOLE; Fiscal Year: 2011
    Lower Urinary Tract Symptoms(LUTS) due to benign prostatic hyperplasia (BPH) are one ofthe most common disorders ofthe aging male...
  60. BPH AND PROSTATE CA IN 5A-REDUCTASE-2 DEFICIENT CARRIERS
    Julianne Imperato McGinley; Fiscal Year: 2000
    ..that a mild decrease in dihydrotestosterone (DHT) throughout life will prevent the development of benign prostatic hyperplasia and prostate cancer...
  61. Profiling Urine Glycosylation of PSA and other Glyco-Biomarkers in Prostate Cance
    Lewis Pannell; Fiscal Year: 2009
    ..establishing a clinically pertinent assay for the characterization of PSA (and PAP) produced in PC, benign prostatic hyperplasia (BPH) and that released by healthy cells, one that can be reliably used for the early detection, prognosis ..
  62. Alternative Therapies for Benign Prostatic Hyperplasia (CAMUS)
    JOHN CURTIS NICKEL; Fiscal Year: 2010
    ..The 11 CAMUS clinical centers initiated recruitment June 5, 2008 and successfully completed randomization of 369 subjects on April 17, 2009. PUBLIC HEALTH RELEVANCE: Statement not given. ..
  63. UROLOGIC RESEARCH CAREER DEVELOPMENT PROGRAM (T32)
    DOLORES JEAN LAMB; Fiscal Year: 2013
    ..and growth factor signaling, male reproductive biology, genetics, cell cycle control, human benign prostatic hyperplasia, gene therapy and gene disruption. The trainees will be Ph.D. and M.D...
  64. MEDICAL THERAPY IN BENIGN PROSTATIC HYPERPLASIA
    Michael Lieber; Fiscal Year: 2001
    Two different types of medical therapy for the symptoms of benign prostatic hyperplasia (BPH) now have been approved by the U.S. Food and Drug Administration...
  65. Prolactin and Estrogens as Mitogens in Prostate Cancer
    Nira Ben Jonathan; Fiscal Year: 2002
    ..Overproduction of PRL by prostate cells results in prostatic hyperplasia in mice...
  66. Cohort Study of Risks for Benign Prostatic Hyperplasia
    Alan Kristal; Fiscal Year: 2005
    ..is to understand relationships among hormonal, genetic and behavioral risk factors for symptomatic benign prostatic hyperplasia (BPH)...
  67. DIAGNOSTIC CENTER
    M Lucia; Fiscal Year: 2004
    ..The investigators describe the widespread economic and medical problems associated with benign prostatic hyperplasia. The overall goal of the study is to test the effectiveness of pharmacological intervention in benign ..
  68. MPSA Pathology Coordinating Center
    M Lucia; Fiscal Year: 2004
    Benign prostatic hyperplasia (BPH) is the most common proliferative disease of the prostate in men in the United States. More than two thirds of men over age 50 have some degree of BPH. Treatment for BPH approaches $5 billion annually...
  69. Formulated Phytosterols - A New Treatment For Benign Prostatic Hyperplasia
    CURTIS SPILBURG; Fiscal Year: 2006
    unreadable] DESCRIPTION (provided by applicant): Benign prostatic hyperplasia (BPH) refers to the enlargement of the prostate gland, which occurs in 50% of 60-year old men with increasing incidence with age...
  70. MEDICAL THERAPY FOR BPH--DATA COORDINATING CENTER
    PAMELA BURROWS; Fiscal Year: 2001
    ..Data Coordinating Center (DCC) for a proposed multi-center clinical trial of the medical therapy of benign prostatic hyperplasia (BPH)...
  71. MEDICAL THERAPY OF PROSTATIC SYMPTONS (MTOPS)
    Kevin McVary; Fiscal Year: 2001
    ..for consideration for one of 14 Clinical Centers in an expanded trial of Medical Therapy in Benign Prostatic Hyperplasia (BPH)...
  72. PROSTATIC GLUTATHIONE S-EPOXIDE TRANSFERASES
    CARL SCHAFFNER; Fiscal Year: 1991
    ..prostate gland detected just prior to and invariably with the development of the male diseases of benign prostatic hyperplasia and prostatic carcinoma...
  73. PORT-II FOR PROSTATIC DISEASES
    Michael Barry; Fiscal Year: 1999
    ..Benign prostatic hyperplasia (BPH) and carcinoma of the prostate (CAP) are two exceedingly common diseases of older men; 40% of men ..
  74. ROLE OF FIBROBLAST GROWTH FACTORS IN PROSTATE GROWTH
    Michael Ittmann; Fiscal Year: 2003
    DESCRIPTION (Adapted from the Applicant's Abstract): Benign prostatic hyperplasia (BPH) is an extremely common disease of older men which leads to morbidity by obstructing urine outflow...
  75. Cell Growth Inhibiton and Estrogen Action
    Barry Markaverich; Fiscal Year: 2004
    ..of MeHPLA-related compounds with antiproliferative activities and potential for the treatment of benign prostatic hyperplasia, endometriosis, breast and prostatic cancer...
  76. University of Michigan O'Brien Center for Urology Res.
    Mark Day; Fiscal Year: 2007
    ..The findings will have implications for the pathophysiology of benign prostatic hyperplasia (BPH). In Project 2, Dr...